Results 41 to 50 of about 1,210,671 (242)

Histological evaluation of PD-L1 antibody in Head and Neck Squamous Cell Carcinomas (HNSCC)

, 2023
The thesis delves into the critical role of programmed death-ligand 1 (PD-L1) in Head and Neck Squamous Cell Carcinoma (HNSCC). PD-L1, a transmembrane protein found in tumor cells and immune cells, is expressed in higher amounts in specific cancer types,
Picanco Silva, Yasmin
core   +1 more source

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors

Molecular Oncology
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy.
Anna Hernández‐Prat, Alejo Rodriguez‐Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí‐Llucià, Luis Soria‐Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere‐Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira, Joaquim Bellmunt   +16 more
doaj   +1 more source

Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients

Journal of the Egyptian National Cancer Institute, 2018
Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
Dina M. El-Guindy, Duaa S. Helal, Nesreen M. Sabry, Mohamed Abo El-Nasr   +3 more
doaj   +1 more source

Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients

Molecular Oncology, 2023
Alternative sources of tumour information need to be explored in patients with non‐small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD‐L1) expression on cytology imprints and circulating tumour cells (CTCs) with PD‐L1 ...
Mustafa Abdo, Yassine Belloum, David Heigener, Lutz Welker, Sönke vonWeihe, Milena Schmidt, Nadine Heuer‐Olewinski, Iris Watermann, Marlen Szewczyk, Jolanthe Kropidlowski, Thais Pereira‐Veiga, Hatice Elmas, Sven Perner, Stefan Steurer, Harriet Wikman, Klaus Pantel, Martin Reck   +16 more
doaj   +1 more source

Sex-dependent expression and release of PD-L1 by human endothelial cells

, 2022
noneI checkpoint immunitari sono una classe di molecole che regola negativamente l’infiammazione, trasducendo segnali inibitori per le cellule del sistema immunitario.
MESTRINER, MAURO
core  

PD-L1 blockade after XVir-N-31-anti-PD-L1 infection.pzfx

, 2022
PD-L1 blockade assay 
Moritz Klawitter (13177230)
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

BMC Research Notes, 2020
Objective Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 ...
Markus Tiemann, Vera Samoilova, Dmitri Atiakshin, Igor Buchwalow   +3 more
doaj   +1 more source

Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer

Cell Death and Disease, 2021
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated.
Min Liu, Feng Wei, Jian Wang, Wenwen Yu, Meng Shen, Ting Liu, Dong Zhang, Yang Wang, Xiubao Ren, Qian Sun   +9 more
doaj   +1 more source

Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction [PDF]

Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments.
Deanne, Hayward, Zoe, Goddard, Mark, Searcey, Andrew, Beekman, Marco, Cominetti   +4 more
core   +2 more sources